Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
The changes reflect Mölnlycke’s continued focus on ensuring strong governance and relevant expertise as the company advances its growth journey and works to fulfil its purpose to revolutionise care for people and planet.
“We would like to thank Christian for his valuable contribution to the Mölnlycke Board and welcome Filippa and Thomas in their new roles,” said Karl-Henrik Sundström, Chairman of the Board. “Their experience and perspectives will support Mölnlycke as we continue to develop as a world-leading MedTech company.”
Filippa Stenberg currently serves as Managing Director of Patricia Industries, part of Investor AB, and brings extensive experience in active ownership and healthcare investments. She has served as deputy board member of Mölnlycke since 22 May 2025. Born in 1985, Filippa is a Swedish citizen and holds an M.Sc. in Accounting and Financial Management from the Stockholm School of Economics. Her board assignments include Swedish Orphan Biovitrum AB, Affibody Medical AB and Atlas Antibodies AB.
Thomas Kidane will join the Mölnlycke Board as deputy board member. Born in 1986, he is a Swedish citizen and holds an M.Sc. in Accounting and Financial Management from the Stockholm School of Economics. He is Co-Head of Patricia Industries, a member of Investor AB’s Executive Leadership Team, and serves on the boards of Permobil, Piab Group and Fortnox.
For more information, please contact:
Latest news
-
Mölnlycke Health Care accelerates U.S. growth journey with three wound care product launches
Peachtree Corners, GA. July 7, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.
-
Mölnlycke Health Care announces Andreas Johansson as Interim Chief Financial Officer
Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect.
-
Filippa Stenberg joins Mölnlycke Board of Directors
-
Mölnlycke advocates a holistic approach to healthcare sustainability
New white paper calls for integration of environmental, human and economic metrics in sustainability assessments of medical technologies.
-
Mölnlycke Health Care expands investment in Tamer Mölnlycke Care joint venture
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.
-
Mölnlycke Health Care agrees to acquire leading wound cleansing manufacturer to consolidate its position as global leader in wound care
Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.
-
Mölnlycke signs a EUR 350 million revolving credit facility
On 28 April 2023, Mölnlycke entered into a new EUR 350 million multicurrency revolving credit facility. The facility has a tenor of five years with two one-year extension options and will be used as a backup for general corporate purposes. The facility is a refinancing of the existing and undrawn revolving credit facility signed in 2017.
-
EUR bond issue and tender announcement
Mölnlycke intends to issue a new 10-year EUR bond and launches a tender offer for the outstanding EUR 500m bond due February 2025.
-
In 2023 Mölnlycke was awarded a gold medal for Sustainability by EcoVadis
The world’s largest and most trusted provider of business sustainability ratings - EcoVadis, has awarded Mölnlycke a gold medal for our focus on sustainability. They have ranked us in the top 3% of companies worldwide.